Lexeo offers a cash-backed, high-risk gene therapy bet where a newly FDA-aligned pivotal path could unlock major upside if LX2006 succeeds.
Overview
Lexeo Therapeutics is a pre-commercial genetic medicine company developing one-time AAV gene therapies for severe cardiac and neurodegenerative diseases. Its key programs—LX2006 for Friedreich ataxia cardiomyopathy, LX2020 for PKP2 arrhythmogenic cardiomyopathy, and LX1001 for APOE4 Alzheimer’s—target underlying genetic causes rather than symptoms. The company has no product revenue and depends on financing and milestones, but its lead FA cardiomyopathy indication has high unmet need, clear orphan economics, and a newly defined regulatory path toward accelerated approval.